Valneva SE announced this week that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s...

NewsDesk @bactiman63 Specialty vaccine company, Valneva, announced that the U.S. Food and Drug Administration (FDA) has completed a filing review of its Biologics License Application for Valneva’s single-shot...

By NewsDesk  @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following...

Specialty vaccine company, Valneva, announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. VLA1553 was recently awarded Breakthrough...

By NewsDesk  @infectiousdiseasenews Specialty vaccine company, Valneva announced recently it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553,...

Vaccine company, Valneva, announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya...

Specialty vaccine company, Valneva, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for its single-shot Phase 3 chikungunya vaccine candidate...

Valneva SE, a specialty vaccine company focused on prevention of diseases with major unmet needs, today announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot...

Valneva SE, a specialty vaccine company, announced today the publication of full data from the Phase 1 clinical trial of its chikungunya vaccine candidate, VLA1553, in the peer-reviewed medical journal The...

Valneva SE announced this week that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development plan towards licensure...